A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

INTRODUCTION: Direct-acting antivirals (DAAs) have improved treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD). To facilitate the 2022 update of the Kidney Disease: Improving Global Outcomes (KDIGO) guideline for CKD patients with HCV, we systematically revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Balk, Ethan M., Adam, Gaelen P., Jadoul, Michel, Martin, Paul, Gordon, Craig E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939364/
https://www.ncbi.nlm.nih.gov/pubmed/36815114
http://dx.doi.org/10.1016/j.ekir.2022.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939364/
https://www.ncbi.nlm.nih.gov/pubmed/36815114
http://dx.doi.org/10.1016/j.ekir.2022.11.008

Ejemplares similares